P703 Real world experience of the transition from the intravenous to subcutaneous formulation of vedolizumab in inflammatory bowel disease: A review of current data. (30th January 2023)

• Record Type: Journal Article
• Authors: Agboton, C; Kamble, P
• Is Part Of: Journal of Crohn's and colitis. Volume 17(2023)Supplement 1
• Page Start: i835
• Page End: i837
• Publication Date: 2023-01-30
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjac190.0833
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: Vedolizumab (VDZ), a gut selective antilymphocyte trafficking anti-α 4 β 7 integrin monoclonal antibody indicated for the treatment of IBD. After a 3 doses induction, maintenance can be achieved with a standard 8-weekly (Q8W) regimen, or–at any time during the maintenance– patients can be transitioned to 108 mg subcutaneous (SC) formulation at a standard 2 weekly (Q2W) regimen. Methods: This was a literature review to identify real-world studies on the transition from the IV to SC VDZ. The Pubmed and Embase databases were searched up to October 2022 to identify publications on real-world data on the transition from IV to SC VDZ. Results: In total, 9 studies were identified with a total of 1, 323 IBD patients in the UK (5 studies), Norway, Sweden, Belgium and The Netherlands 1-9 . Two prospective studies reported no loss of effectiveness based on disease activity scores of VDZ after the IV-SC transition 1, 2, along with maintenance of baseline status (status at the time of transition) reported in 84% of patients 1 . Biomarkers stability, including fecal calprotectin and C-reactive protein, were reported in three studies 3-5 . Persistence with VDZ treatment following IV-SC transition was 96% at 6 months and 89% at 12 months in one study 3, while another study reported persistence of 86% at 6 months 6 . A preference for the SC formulation by patients was reported 59% and 56% in two studies 7, 8, with time savings and fewer hospital visits recorded as the main reasons for preference of the SC formulation 7 . Multivariate analysis of patient characteristics in two studies 7, 8 revealed no factor associated with preference for VDZ SC other than younger age in one study 8 . The most frequently reported adverse events with VDZ SC were injections site reactions: 15% and 18% in two studies 1, 5, with transient severe injection site reactions reported in 1% of patients in one study 3 . Conclusion: Real-world data on IBD patients who transitioned from IV to SC VDZ showed no change in effectiveness, with a majority preferring the SC formulation due to time savings and the transition leading to fewer hospital visits. Safety of VDZ SC was generally comparable with that of IV VDZ. References: 1. Ventress E et al J Crohn's Colitis 2022;16:911-21 2. Volkers A et al Aliment Pharmacol Ther 2022;56:1044-54 3. Bergqvist V et al Aliment Pharmacol & Ther 2022;55:1389-1401 4. Mclean M et al Gut 2022;71:A58-A59 5. Wiken T et al J Crohn's Colitis 2022;16:i378-79 6. Lim S et al J Crohn's Colitis 2022;16:i499-i500 7. Alice H et al J Crohn's Colitis 2022;16:i410 8. Asnong K et al J Crohn's Colitis 2022;15:S608-9 9. Maw F et al Gut 2021;70:a91